SDGR — Schrodinger, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1490978 ·
Last close
$15.14
Market Cap
$992.53M
52W High
$17.82
52W Low
$11.56
ADV30
1,211,838
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 58,587,000 | 29,547,000 | -48,794,000 | -60,026,000 | 634,187,000 | 260,255,000 | 320,639,000 |
| Dec 2025 | 87,235,000 | 57,293,000 | -17,157,000 | 32,511,000 | 726,160,000 | 230,517,000 | 362,107,000 |
| Sep 2025 | 54,324,000 | 28,039,000 | -45,947,000 | -32,795,000 | 653,660,000 | 172,120,000 | 332,308,000 |
| Jun 2025 | 54,759,000 | 26,158,000 | -52,903,000 | -43,173,000 | 688,244,000 | 219,901,000 | 345,372,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$13,899,000
Investing CF
$57,898,000
Financing CF
$2,931,000
CapEx
$-1,442,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.38
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-628,806,000
Inventory
—
Receivables
$104,393,000
ST Investments
$164,947,000
EBIT TTM
$-166,896,000
Pretax Income TTM
$-102,326,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$254,904,992
EBITDA
$-158,892,000
Free Cash Flow
$-49,420,624
Enterprise Value
$855,012,096
Total Cash
$398,959,008
Total Debt
$107,008,000
Shares Out
65,556,531
Trailing EPS
$-1.40
Book Value
$4.21
ROE
-30.1%
ROA
-15.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 255,869,000 | -166,896,000 | -103,265,000 | 726,160,000 | 362,107,000 | — | 13,899,000 |
| Dec 2024 | 207,539,000 | -209,296,000 | -187,123,000 | 823,226,000 | 401,781,000 | — | -157,368,000 |
| Dec 2023 | 216,666,000 | -177,448,000 | 40,720,000 | 802,955,000 | 254,397,000 | — | -136,733,000 |
| Dec 2022 | 180,955,000 | -146,817,000 | -149,186,000 | 688,587,000 | 240,682,000 | — | -119,683,000 |
TTM Snapshot
Revenues TTM
$144,689,000
NetIncome TTM
$-175,020,000
OpCashFlow TTM
$0
Assets (Latest)
$823,226,000
Forward EPS
$-1.66
Max Pain — expiry 2026-11-20
max pain strike: $12.50 · spot: $15.14 · call oi: 2,602 · put oi: 3,335
Expected Move to 2026-11-20:
±$4.33
(28.57%) —
implied range
$10.82 –
$19.47
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OPK | OPKO HEALTH, INC. | $985.15M | $1.32 | — |
| OLMA | Olema Pharmaceuticals, Inc. | $1.00B | $11.45 | — |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $969.12M | $6.57 | — |
| AVTX | Avalo Therapeutics, Inc. | $965.48M | $18.25 | — |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $1.03B | $2.31 | — |
News headlines (Yahoo Finance, 1h cache)
What Does Schrodinger Inc (SDGR)’s 2026 Outlook Reveal?
2026-06-21 13:48 · Yahoo
Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery
2026-07-27 11:30 · Yahoo
Schrödinger to Announce Second Quarter 2026 Financial Results on August 5
2026-07-22 12:30 · Yahoo
AMD Is Up 150% This Year But Here Are 5 Overlooked Stocks Betting on What Comes Next
2026-07-01 16:16 · Yahoo
AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity
2026-06-30 13:38 · Yahoo
Morgan Stanley Maintains an Equal Weight” rating on Schrödinger, Inc. (SDGR)
2026-06-23 19:41 · Yahoo
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
2026-06-02 21:32 · Yahoo
How The Schrödinger (SDGR) Investment Story Is Shifting As Analysts Reset Price Targets
2026-05-25 13:14 · Yahoo
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-07-20 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.